These mutations are commonly seen in people with lung adenocarcinoma, which starts in mucus-producing lung cells; younger individuals who are nonsmokers; and Asian patients.
Although EGFR-targeted treatments can slow down the disease, long-term survival remains low, with fewer than 20% of patients surviving after five years, particularly those with exon 20 insertion mutations.
Rybrevant Faspro is injected under the skin and takes about five minutes to administer. It combines two ingredients: amivantamab and hyaluronidase. Amivantamab is a first-in-class fully human lab-made antibody that selectively targets cancer cells with EGFR and mesenchymal–epithelial transition (MET) gene mutations, blocking cancer cell growth signals and helping your immune system identify and kill tumor cells. Hyaluronidase helps improve absorption of the medicine when it is injected under the skin. Lazcluze is an oral targeted cancer medicine that blocks faulty EGFR signals and helps slow or stop the spread of cancer cells. Rybrevant Faspro is the first and only subcutaneous treatment approved for EGFR-mutated NSCLC that provides a quicker and less invasive treatment method that may reduce the time you spend at the clinic and make it easier for you to follow your treatment plan. Additionally, it offers a chemotherapy-free frontline option for people with advanced or spreading lung cancer. Rybrevant Faspro is approved for the same uses as Rybrevant and can be used in EGFR-positive NSCLC as a first treatment or after other treatments stop working, either with Lazcluze, with chemotherapy, or alone, depending on the EGFR mutation and prior therapy.
Why Was It Approved?
The FDA approval of Rybrevant Faspro was based on clinical studies showing it was safe and equally as effective as its IV version for treating EGFR-mutated NSCLC when combined with Lazcluze, with fewer administration-related reactions and improved overall survival. In a study of 418 patients with EGFR-mutated advanced NSCLC whose disease progressed after osimertinib and platinum-based chemotherapy, 206 received SC Rybrevant Faspro and 212 received IV Rybrevant, both combined with Lazcluze. Results showed thatsubcutaneous Rybrevant Faspro achieved similar blood medicine levels as the IV form. Response rates were comparable, with 30% and 33% of patients benefitting from the subcutaneous and IV forms, respectively. However, patients went longer without their cancer worsening with the subcutaneous versus IV form (6.1 vs. 4.3 months), and overall survival improved. After a year, more patients on the subcutaneous form were alive compared with those treated with the IV form (65% vs. 51%). Fewer patients on Rybrevant Faspro had infusion reactions (13% vs. 66%) or blood clots (9% vs. 14%) than those on IV Rybrevant. Treatment was much faster with Rybrevant Faspro (median administration time, 4.8 minutes vs. five hours), and more patients compared with those on IV Rybrevant considered it to be very convenient or convenient (85% vs. 52% at first dose and 85% vs. 35% at the end of treatment).
What Do I Need to Know?
Rybrevant Faspro is given by a health care provider as an injection under the skin, usually in the belly, and takes about five minutes to administer. At first, you’ll get it once a week, and later it may be given every two weeks. Your health care provider will decide your dosing schedule depending on your weight and treatment plan. If you miss an appointment, contact your health care provider immediately to reschedule.
